Literature DB >> 15791513

Safety profile of smallpox vaccine: insights from the laboratory worker smallpox vaccination program.

James Baggs1, Robert T Chen, Inger K Damon, Lisa Rotz, Christopher Allen, Kathleen E Fullerton, Christine Casey, Dale Nordenberg, Gina Mootrey.   

Abstract

BACKGROUND: The frequency of mild-to-moderate adverse events following smallpox vaccination was not well documented or reported during the pre-eradication era. This report describes the frequency of such symptoms among 936 adult smallpox vaccinees with and without a history of prior smallpox vaccination.
METHODS: Diary cards were distributed to 1006 laboratory workers and members of the Centers for Disease Control and Prevention (CDC) smallpox response team who received smallpox vaccination under an investigational new drug protocol during 2001-2002. Vaccinees were requested to complete the diary card daily and return it to the CDC 28 days after vaccination. The proportion of vaccinees reporting symptoms was determined and compared among subgroups.
RESULTS: Ninety-three percent of the diary cards were returned. The most common symptom reported was "itching at vaccination site." Primary vaccines reported statistically higher proportions of the following 11 symptoms: joint pain (25% vs. 11%; P=.0011), muscle pain (46% vs. 19%; P<.0001), fatigue (43% vs. 29%; P=.0161), swelling at vaccination site (58% vs. 33%; P<.0001), itching on the body (31% vs. 17%; P=.0048), abdominal pain (11% vs. 2%; P=.0012), swollen or tender lymph nodes (71% vs. 33%; P<.0001), pain at injection site (48% vs. 30%; P=.0018), headache (40% vs. 25%; P=.0088), backache (17% vs. 7%; P=.0090), and fever (temperature, >or=100 degrees F [37.7 degrees C]; 20% vs. 9%; P=.0047).
CONCLUSIONS: This analysis suggests that previously unvaccinated persons aged <30 years experienced more symptoms than did previously vaccinated persons. The findings of increased proportions with joint pain, abdominal pain, backache, and difficulty breathing were unexpected. As with recently described cardiac adverse events, these symptoms are suggestive of systemic involvement and warrant further study.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15791513     DOI: 10.1086/428731

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  8 in total

1.  Evaluation of therapeutic interventions for vaccinia virus keratitis.

Authors:  Sharon Altmann; Curtis R Brandt; Christopher J Murphy; Ravi Patnaikuni; Teresa Takla; Megan Toomey; Brittany Nesbit; Kimberly McIntyre; Jill Covert; Richard Dubielzig; Gary Leatherberry; Elizabeth Adkins; Shantha Kodihalli
Journal:  J Infect Dis       Date:  2011-01-28       Impact factor: 5.226

2.  A quantitative rabbit model of vaccinia keratitis.

Authors:  Sharon Altmann; Andrew Emanuel; Megan Toomey; Kim McIntyre; Jill Covert; Richard Redd Dubielzig; Gary Leatherberry; Christopher J Murphy; Shantha Kodihalli; Curtis R Brandt
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-04-07       Impact factor: 4.799

3.  Inhibition of Vaccinia virus entry by a broad spectrum antiviral peptide.

Authors:  S E Altmann; J C Jones; S Schultz-Cherry; C R Brandt
Journal:  Virology       Date:  2009-04-22       Impact factor: 3.616

4.  Neurologic adverse events associated with smallpox vaccination in the United States--response and comment on reporting of headaches as adverse events after smallpox vaccination among military and civilian personnel.

Authors:  Walter R Schumm
Journal:  BMC Med       Date:  2006-11-10       Impact factor: 8.775

5.  A prospective study of the incidence of myocarditis/pericarditis and new onset cardiac symptoms following smallpox and influenza vaccination.

Authors:  Renata J M Engler; Michael R Nelson; Limone C Collins; Christina Spooner; Brian A Hemann; Barnett T Gibbs; J Edwin Atwood; Robin S Howard; Audrey S Chang; Daniel L Cruser; Daniel G Gates; Marina N Vernalis; Marguerite S Lengkeek; Bruce M McClenathan; Allan S Jaffe; Leslie T Cooper; Steve Black; Christopher Carlson; Christopher Wilson; Robert L Davis
Journal:  PLoS One       Date:  2015-03-20       Impact factor: 3.240

6.  Polycyclic N-benzamido imides with potent activity against vaccinia virus.

Authors:  Eva Torres; María D Duque; Pelayo Camps; Lieve Naesens; Teresa Calvet; Mercè Font-Bardia; Santiago Vázquez
Journal:  ChemMedChem       Date:  2010-12-03       Impact factor: 3.540

7.  First discovery of novel 3-hydroxy-quinazoline-2,4(1H,3H)-diones as specific anti-vaccinia and adenovirus agents via 'privileged scaffold' refining approach.

Authors:  Dongwei Kang; Heng Zhang; Zhongxia Zhou; Boshi Huang; Lieve Naesens; Peng Zhan; Xinyong Liu
Journal:  Bioorg Med Chem Lett       Date:  2016-09-29       Impact factor: 2.823

8.  Genomic identification of human vaccinia virus keratoconjunctivitis and its importance as a laboratory-acquired infection.

Authors:  Zahra Movahedi Motlagh; Azam Mokhtari; Mohammadreza Mahzounieh
Journal:  Indian J Ophthalmol       Date:  2016-11       Impact factor: 1.848

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.